Charts NXS, page-829

First 829 Last

Share
Profile

Follow
DAngel35

271 Posts.

125

09/01/22

21:52

Post #: 58739454
Share

Originally posted by sabine: ↑

Happy New Year to everyone,
….. and here is NXS marking time STILL.

Which - given the efficacy of the product - makes me shake my head.

And @jb5757, Dustin Haines, the COO is still up there on Linkedin. Are you able to enlarge on your rumours please?

And (to the powers that be) where’s the update from Zimmer Biomet that was spoken of in Judith Mitchell’s video presentation of last November 11?
[ref] Excerpt :
We made an announcement way back in June that our Bactisure partner, Zimmer Biomet had filed a law suit against us because they want access to Xperience
We’ve not quite finalised that negotiation but I guess the thing I”d like people to know is that we’re in we a very positive space
Zimmer see the benefits if adding Xperience to Bactisure and we see a pathway forward
so I am happy to think we get that resolved before we go into the new year….

So November 11 was eight weeks ago. And if the issue has been resolved there has been no word as yet.

Which leads me into venting some opinions on management:
In my opinion the leaders here do not present as experienced tier one operators for several reasons including the ‘start as you mean to go on’ deal with 3M which was a complete disaster.
NXS has a fantastic product range but - after years - it is still not widely available on pharmacy shelves.

Back in 2020 Judith put out a presentation noting - amongst other things - how superior XPerience (and all Xbio formulas) is to Betadine.

It is a product that can help hundreds of thousands of people.
Why can’t I buy it at the supermarket?

And what about some updates on all the research that was underway … And the petcare side of things, dental products and so much else?

TBH I think Next Science may have been hoping all along to pass the company on so more competent hands could take it forward rather than doing it itself.
And it still is?
Yet at $1.26 a share and the market cap just under $250m today, noone is rushing to buy ?

..It will be interesting to see how the Zimmer Biomet case is resolved.
And to see the December quarterly report (last year published on Jan 28, 2021)

cheers

[Reminder of 26/08/20 Presentation]
spoiler: Two slides

Expand

Xperience is used in surgical operations, not to be sold on the shelves in a supermarket/pharmacy.

Also am pretty sure the company said some time ago it decided to change up the product pipeline to prioritise Xperience given it was the product in which they saw the fastest potential for revenue growth, hence the latest presentation slides have a strong focus on it rather than all those future products you highlighted.

Personally I'm not expecting a super strong quarterly update given Omicron probably has had an impact on elective surgeries in the US, key would be the number of hospitals and surgeons that are now using the product itself (last count 54/110 respectively), hopefully as US hospital system normalises the volume from existing users naturally goes up.

Your comment on Zimmer Biomet is fair though, let's see what she says in the next investor update call.

NXS Price at posting: $1.26 Sentiment: Buy Disclosure: Held
7 Upvote

1 Great analysis

Reply

Top Stories

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

What's causing the cost-of-living crisis, and how to navigate it